New report: Stakeholder Insight: Acute Leukemias - Reaching the limits of cytotoxic chemotherapy

Dec. 12, 2009 - PRLog -- The drug therapy of acute myeloid leukemia (AML) and adult acute lymphoblastic leukemia (ALL) is largely based on chemotherapy regimens that have changed little in the past few decades. Patient outcomes for both diseases remain poor, particularly for elderly and high-risk patients. As the limits of cytotoxic chemotherapy are being reached, an unmet need remains for novel, improved therapies.

Scope

* Analysis of the AML and adult ALL market based on a survey of 180 acute leukemia specialists, supported by interviews with key opinion leaders.
* Segmentation of the AML and adult ALL populations by age group and risk group, respectively
* In-depth analysis of treatment patterns, regimens prescribed and treatment outcomes for AML and adult ALL by age group and risk group, respectively
* Discussion of unmet needs and overview of late-stage pipeline drugs and marketed drugs investigated for expansion into the AML and adult ALL settings

Highlights

The only molecular targeted therapy approved for use in AML is Mylotarg (gemtuzumab ozogamicin; Wyeth) but it's use is limited to elderly, relapsed patients who are not candidates for other chemotherapy. A number of molecular targeted therapies are currently in development for AML but are expected to have minimal impact on patient outcomes.

Gleevec (imatinib; Novartis) is the only molecular targeted therapy used extensively in the treatment of adult ALL. To date, the second generation tyrosine kinase inhibitors Sprycel (dasatinib; Bristol-Myers Squibb) and Tasigna (nilotinib; Novartis) have limited use in the treatment of the disease.

Hematopoietic stem cell transplantation (HSCT) has a central role in the management of both AML and adult ALL. However, it remains an underutilized procedure and its use is often delayed beyond its optimal timing. Research efforts are required to optimize the use of this potentially curative approach.

Partial Table of Contents:
-- Full ToC is available at http://www.fastmr.com/catalog/product.aspx?productid=4300...

ABOUT DATAMONITOR HEALTHCARE
About the Oncology pharmaceutical analysis team
CHAPTER 1 EXECUTIVE SUMMARY
Scope of the analysis
Datamonitor insight into the acute leukemias market
Datamonitor insight into the AML market
Datamonitor insight into the adult ALL market
Contributing experts
Related reports
Upcoming reports
CHAPTER 2 INTRODUCTION AND SCOPE
Coverage of the Stakeholder Insight Survey
Disease definition and epidemiology
Segmentation of the acute leukemia population
Current drug treatment practice for AML and adult ALL
Key unmet needs within the AML and adult ALL market
Overview of pipeline drugs for AML and adult ALL
CHAPTER 3 AML: COUNTRY TREATMENT TREES
Introduction
Acute myeloid leukemia (AML) country treatment trees
US
Japan
France
Germany
Italy
Spain
UK
CHAPTER 4 AML: PATIENT SEGMENTATION AND EPIDEMIOLOGY
Key findings
Definition of acute myeloid leukemia (AML)
AML is a disease of older age
Presentation and diagnosis
Symptoms can vary for AML patients
Segmentation of the acute myeloid leukemia (AML) population
Two classification systems are used in AML
Cytogenetics is the most important prognostic factor
Age is a major determinant of survival
Epidemiology of acute myeloid leukemia (AML)
AML accounts for about 30-35% of all leukemias in the seven major markets
Forecast incidence of AML in the seven major markets, 2009-2019
CHAPTER 5 AML: TREATMENT TRENDS
Key findings
Summary of acute myeloid leukemia (AML) treatment strategies
Treatment rates
Induction treatment
Induction treatment overview
Induction treatment trends in patients less than 60 years old
Standard-dose cytarabine with idarubicin is the most popular regimen
There is a low uptake of the hypomethylating agents Vidaza and Dacogen
Induction treatment trends in patients aged 60 or above
The treatment of older AML patients deviates from treatment guidelines
The uptake of Vidaza and Dacogen is significant in the US
Post-induction treatment
Post-induction treatment overview
Post-induction treatment trends in patients less than 60 years old
Post-induction treatment trends in patients aged 60 or above
Consolidation treatment
Consolidation treatment overview
Consolidation treatment trends in patients less than 60 years old
Consolidation treatment trends in patients aged 60 or above
Relapse treatment
Relapse treatment overview
Relapse treatment trends in patients less than 60 years old
Relapse treatment trends in patients aged 60 or above

For more information or to purchase this report, go to http://www.fastmr.com/catalog/product.aspx?productid=43008

About Datamonitor

The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment.  View more research from Datamonitor at http://www.fastmr.com/catalog/publishers.aspx?pubid=1002

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.